查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球神經診斷學市場 - 2023-2030年
市場調查報告書
商品編碼
1297822

全球神經診斷學市場 - 2023-2030年

Global Neurodiagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球神經診斷市場在2022年達到75億美元，預計到2030年將見證有利可圖的成長，達到132億美元。在2023-2030年的預測期內，全球神經診斷市場預計將呈現7.6%的複合成長率。

神經診斷測試可以在早期階段發現神經系統的異常，甚至在症狀變得明顯之前。這種早期檢測允許及時干涉和治療，有可能防止病情的進一步損害或發展。神經診斷可以幫助區分可能具有類似症狀的不同神經系統疾病。

阿滋海默症、肌萎縮性脊髓側索硬化症、亨廷頓病、帕金森氏症和脊髓性肌肉萎縮症等神經系統疾病的發病率上升，將在預測期內推動對神經診斷產品的需求。

市場動態

技術進步將推動神經診斷市場的成長

神經診斷的技術進步大大提高了評估和了解神經系統結構和功能的能力。例如，腦電圖使用放置在頭皮上的電極測量大腦中的電活動。最近的進展包括高密度腦電圖陣列，它有更多的電極，能夠更精確地定位大腦活動並提高空間解析度。

此外，PET成像涉及將放射性示踪劑注入體內，可用於測量大腦中的血流、代謝和特定分子過程。 PET成像的最新進展包括開發新型示踪劑，可以針對特定的神經過程或受體，提供對神經化學異常的寶貴見解。因此，技術進步推動了市場成長。

診斷和程序的高成本將阻礙市場的成長

採用成像技術需要大量投資，這些技術的高成本限制了它們的使用，特別是在發展中國家和低收入國家的醫療機構。一台CT掃描儀的成本從35,000美元到100,000美元不等，有些設備的成本要高得多。

另一方面，一台PET掃描儀大約需要250萬美元，而一台MRI掃描儀大約需要200萬美元。這些費用被認為是過於昂貴，阻礙了市場的採用和擴展。

COVID-19影響分析

由於大流行，許多醫療機構和診斷中心不得不將資源優先用於COVID-19檢測和治療。這導致非緊急的神經診斷服務暫時中止或減少，導致病人的程序和測試被延遲或推遲。 COVID-19大流行病對全球的心理健康產生了重大影響。

壓力、焦慮和抑鬱水平的提高會影響神經功能，可能需要進行額外的神經診斷評估。神經診斷法可以在評估和監測該大流行病對心理健康的神經系統影響方面發揮作用。然而，它也加速了遠程醫療和遠程監測的採用，為未來改善可及性和病人護理提供了機會。

俄羅斯-烏克蘭戰爭影響分析

俄羅斯-烏克蘭戰爭估計對全球神經診斷學市場的影響很小，因為該地區流行率低，沒有關鍵的市場參與者。然而，在預測期內，原料、測試產品和設備的進出口的影響預計對全球神經診斷市場的影響很小。

人工智慧影響分析

人工智慧預計將對全球子癇前期市場產生積極的影響。由於人工智慧可以分析個別病人的數據，包括遺傳資訊、病史和成像結果，以產生個性化的治療計劃。

通過考慮多種因素並根據每個病人的具體需求進行干涉，人工智慧可以最佳化治療效果並減少不良反應。人工智慧可以分析患者個人數據，包括遺傳資訊、病史和成像結果，以生成個性化的治療計劃。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按產品抽查
  • 按情況分析
  • 按終端用戶分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 神經系統疾病的發病率不斷上升
      • 技術進步
    • 限制因素
      • 診斷和手術費用高
    • 機會
      • 攜帶式、可穿戴式和移動式神經診斷設備的發展
    • 影響分析

第五章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第六章：COVID-19分析

  • 對COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：人工智慧影響分析

第九章：按產品分類

  • 診斷和成像系統
    • 電腦斷層掃描（CT）掃描儀
    • 腦電圖（EEG）系統
    • 位置發射斷層掃描（PET）系統
    • 肌電圖（EMG）產品
    • 超音波成像系統
    • 腦磁圖（MEG）系統
    • 血管造影系統
    • 其他系統
  • 臨床檢驗儀器
    • 聚合酶鏈反應(PCR)
    • 下一代測序(NGS)
    • 桑格測序儀
    • 其他臨床診斷產品
  • 試劑和消耗品
    • 酶、蛋白質和多肽
    • 緩沖劑
    • 探針
    • 培養基和血清
    • 溶劑
    • 抗體
    • 其他試劑

第十章：按病情分類

  • 神經退行性疾病
  • 癲癇
  • 中風
  • 頭痛症
  • 睡眠障礙
  • 其他

第11章：按終端用戶分類

  • 醫院和手術中心
  • 非住院護理中心
  • 診斷實驗室和影像中心
  • 神經病學中心
  • 其他

第十二章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第13章：競爭格局

  • 競爭格局
  • 市場佔有率分析
  • 合併和收購分析

第十四章：公司簡介

  • Hoffman-La Roche AG
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Hitachi Ltd
  • FUJIFILM Holdings Corporation
  • Mitsar Co Ltd
  • Thermo Fischer Scientific Inc
  • Bio-Rad Laboratories
  • QIAGEN NV

第十五章：附錄

簡介目錄
Product Code: MD5095

Market Overview

The Global Neurodiagnostics Market reached US$ 7.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 13.2 billion by 2030. The global neurodiagnostics market is expected to exhibit a CAGR of 7.6% during the forecast period 2023-2030.

Neurodiagnostic tests can detect abnormalities in the nervous system at an early stage, even before symptoms become apparent. This early detection allows for timely intervention and treatment, potentially preventing further damage or progression of the condition. Neurodiagnostics can help differentiate between different neurological conditions that may have similar symptoms.

The rising incidence of neurological illnesses such as Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and spinal muscular atrophy will drive demand for neurodiagnostic products over the projected period.

Market Dynamics

Technological Advancements will Drive the Neurodiagnostics Market Growth

Technological advancements in neuro diagnostics have greatly improved the ability to assess and understand the structure and function of the nervous system. For instance, EEG measures electrical activity in the brain using electrodes placed on the scalp. Recent advancements include high-density EEG arrays, which have a larger number of electrodes, enabling more precise localization of brain activity and improved spatial resolution.

Additionally, PET imaging involves injecting a radioactive tracer into the body, which can be used to measure blood flow, metabolism and specific molecular processes in the brain. Recent advancements in PET imaging include the development of novel tracers that can target specific neurological processes or receptors, providing valuable insights into neurochemical abnormalities. As a result, technological advancements drive market growth.

High Cost of Diagnosis and Procedure will Hamper the Market Growth

Adoption of imaging technology involves significant investment and the high cost of these technologies limits their utilisation, particularly in healthcare facilities in developing and low-income nations. The cost of a CT Scanner can range from $35,000 to $100,000, with some devices costing considerably more.

A PET scanner, on the other hand, costs around USD 2.5 million, while an MRI scanner costs around USD 2 million. These sums are seen as prohibitively expensive, impeding market adoption and expansion.

COVID-19 Impact Analysis

Due to the pandemic, many healthcare facilities and diagnostic centers had to prioritize resources for COVID-19 testing and treatment. This resulted in the temporary suspension or reduction of non-urgent neurodiagnostic services, leading to delayed or postponed procedures and tests for patients. The COVID-19 pandemic has had a significant impact on mental health globally.

Increased levels of stress, anxiety, and depression can influence neurological function and may require additional neurodiagnostic evaluations. Neurodiagnostics can play a role in assessing and monitoring the neurological effects of the pandemic on mental health. However, it has also accelerated the adoption of telemedicine and remote monitoring, providing opportunities for improved accessibility and patient care in the future.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global neurodiagnostics market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products and devices is anticipated to have little influence over the global neurodiagnostics market in the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact the global preeclampsia market positively . Due to AI can analyze individual patient data, including genetic information, medical history and imaging results, to generate personalized treatment plans.

By considering multiple factors and tailoring interventions to the specific needs of each patient, AI can optimize treatment efficacy and reduce adverse effects. AI can analyze individual patient data, including genetic information, medical history and imaging results, to generate personalized treatment plans.

Segment Analysis

The global neurodiagnostics market is segmented based on product, condition, end user and region.

The Diagnostic & Imaging Systems Segment is Estimated to Hold the Majority of the Neurodiagnostics Market Share During the Forecast Period

The diagnostic & imaging systems product holds about 53.7% of the total neuro diagnostics market in the forecast period. The increasing number of product launches by the key players helps to drive the market.

For instance, on November 28, 2022, Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global pioneer in revolutionary diagnostic imaging technology, announced the release of SP Configurations, Orian SP, and Galan SP. This recent release includes AI-driven workflow solutions, an intelligent Ceiling Camera and the Tablet UX mobile interface, and is intended to deliver high-end performance daily.

And on February 28, Hyperfine, Inc., the pioneering medical device firm that developed the Swoop system, the world's first FDA-cleared portable MRI system, announced the 510(k) clearance of the newest upgrade to its Swoop system software. The category is predicted to grow throughout the projection period as a result of the aforementioned factors.

Geographical Analysis

Europe is Estimated to Hold the Second Largest Share of the Global Neurodiagnostics Market During the Forecast Period

The Europe region holds the second largest share of the global neurodiagnostics market accounting for approximately 27.7% in the forecast period. With the collaborations between major parties rising, as is public awareness of neurological illnesses and brain health. For instance, on December 12, 2022, Natus Medical Inc. secured a contractual contract with Micromed Group SpA, an EU-based provider of neurophysiology solutions.

The transaction is scheduled to close in the first quarter of 2023, subject to regulatory approval from the French Ministry of Economy and Finance and the Italian Council of Ministers Presidency. The goal of this agreement is to provide access to a single portfolio of neuromonitoring and neurodiagnostic equipment to the EU and the rest of the world.

Competitive Landscape

The major global players in the market include: Hoffman-La Roche AG, GE Healthcare, Siemens Healthineers, Philips Healthcare, Hitachi Ltd, Fujifilm Holdings Corporation, Mitsar Co Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories, Qiagen NV, among others.

Why Purchase the Report?

  • To visualize the global neurodiagnostics market segmentation based on product, condition, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of neuro diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Neurodiagnostics Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Condition
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of neurological diseases
      • 4.1.1.2. Technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnosis and procedure
    • 4.1.3. Opportunity
      • 4.1.3.1. The development of portable, wearable and mobile neurodiagnostic devices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Impact Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Diagnostic & Imaging Systems
    • 9.2.1. Computed Tomography (CT) Scanner
    • 9.2.2. Electroencephalogram (EEG) Systems
    • 9.2.3. Position emission tomography (PET) System
    • 9.2.4. Electromyography (EMG) Products
    • 9.2.5. Ultrasound Imaging Systems
    • 9.2.6. Magnetoencephalogram (MEG) System
    • 9.2.7. Angiography System
    • 9.2.8. Other Systems
    • 9.2.9. Introduction
    • 9.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinical Testing Instruments
    • 9.3.1. Polymerase Chain Reaction (PCR)
    • 9.3.2. Next Generation Sequencing (NGS)
    • 9.3.3. Sanger Sequencing
    • 9.3.4. Other Clinical Diagnostic Products
  • 9.4. Reagents & Consumables
    • 9.4.1. Enzymes, Protein & Peptides
    • 9.4.2. Buffers
    • 9.4.3. Probes
    • 9.4.4. Media and Serra
    • 9.4.5. Solvents
    • 9.4.6. Antibodies
    • 9.4.7. Other Reagents

10. By Condition

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 10.1.2. Market Attractiveness Index, By Condition
  • 10.2. Neuro Degenerative Disease
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Epilepsy
  • 10.4. Stroke
  • 10.5. Headache Disorder
  • 10.6. Sleep Disorder
  • 10.7. Others

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospital and Surgery Centers
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Ambulatory Care Centers
  • 11.4. Diagnostic Laboratories & Imaging Centers
  • 11.5. Neurology Centers
  • 11.6. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Hoffman-La Roche AG
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. GE Healthcare
  • 14.3. Siemens Healthineers
  • 14.4. Philips Healthcare
  • 14.5. Hitachi Ltd
  • 14.6. FUJIFILM Holdings Corporation
  • 14.7. Mitsar Co Ltd
  • 14.8. Thermo Fischer Scientific Inc
  • 14.9. Bio-Rad Laboratories
  • 14.10. QIAGEN NV

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us